Supplier Corrective Action Requests: When to Issue One and What Your Analytical Testing Laboratory Needs First

A shipment of ashwagandha root extract arrives with a certificate of analysis showing 5.2% withanolides. Your incoming QC test comes back at 2.1%. The supplier’s quality contact insists it’s a “sampling issue.” At that moment, you have two choices: accept the material under a deviation, or issue a Supplier Corrective Action Request and demand a real explanation. Most quality teams know what a SCAR is. Far fewer know how to make one actually work — or what their analytical testing laboratory needs to generate before the request goes out.

What Actually Warrants a SCAR — and What Doesn’t

Not every failed batch merits a formal corrective action request. A single minor deviation on a rarely-tested secondary parameter might warrant a note-to-file and a phone call. A SCAR, by contrast, is a formal quality record. It triggers obligations on both sides, creates a paper trail regulators can review, and puts your supplier on notice that continued failures have consequences.

The triggers that justify a SCAR typically fall into four categories.

Out-of-specification test results. Potency, identity, or purity values that fall outside your approved incoming specifications. Under 21 CFR Part 111.70, dietary supplement manufacturers are required to establish written specifications for every component and verify incoming materials against them. When a result fails, the system-level question is why — and that question lives in a SCAR.

COA discrepancies. When your laboratory’s data doesn’t match the values on the supplier’s certificate of analysis, you’re dealing with something more serious than a simple OOS result. A gap that large raises questions about the integrity of the supplier’s own testing program — questions that deserve formal answers.

Microbial exceedances. Total Aerobic Count (TAC) or specific pathogen results that exceed your approved limits. For botanical raw materials, USP-aligned specifications commonly used in the industry include ≤100,000 CFU/g TAC and ≤1,000 CFU/g combined yeast and mold — but your approved, validated specifications govern, not generic industry benchmarks.

Pattern failures. Two or more non-conformances from the same supplier within a rolling 12-month window, even if each incident seemed minor individually. A pattern is evidence of a systemic quality problem that a single conversation won’t fix.

What doesn’t warrant a SCAR by default: administrative errors with no quality impact (incorrect lot number formatting, missing secondary label), one-time logistical failures, or results on parameters your SOPs classify as informational rather than release-critical.

The Documentation Your Analytical Testing Laboratory Must Generate First

This is where most manufacturers stumble. A SCAR without solid analytical backing is just a complaint — and a competent supplier quality team will probe every gap in your supporting data. Before the request goes out, your analytical testing laboratory should have the following in order.

A full, signed test report with the method cited by name and version. If potency was measured by HPLC-UV, the report should reference the validated method identifier, column type, reference standard used, and instrument ID. “HPLC assay — FAIL” is not a test report. It’s a conclusion without a foundation, and it gives the supplier grounds to dispute your results.

Raw instrument data. Chromatograms, spectral overlays, and integration tables aren’t optional support documents — they’re the scientific core of your case. An analytical testing laboratory accredited to ISO 17025 archives raw data as a matter of standard practice. Internal QC labs should be doing the same, consistent with 21 CFR Part 11 data integrity requirements where electronic records are involved.

Chain of custody documentation. From the moment the sample was drawn from the receiving lot to when the result was reported, every transfer and storage condition should be logged. If a supplier’s response alleges sample mishandling on your end, you need documentation to rebut it — and without it, the dispute becomes word against word.

A reserve sample retention record. Pull and retain at least twice the quantity needed for a full retest from the failing lot, stored at the appropriate conditions. You may need it for referee testing, for the supplier to run a side-by-side comparison, or for a potential regulatory inquiry down the road.

Method comparison data, where applicable. This comes up constantly in botanical ingredients. Your contract analytical testing laboratory may be using HPLC fingerprinting or DNA barcoding for identity confirmation, while your supplier’s COA is based on macroscopic and microscopic examination per USP <561> Articles of Botanical Origin. The methods aren’t equivalent. If you’re going to argue that the supplier’s result is wrong, you need to either establish that your method is the controlling one per your approved specifications, or document the method discrepancy clearly in the SCAR and address it head-on.

One issue we see regularly: manufacturers issue a SCAR based on a first-run OOS result, skipping the internal laboratory investigation phase. Under a rigorous quality system, an initial OOS result should trigger an internal review — calculation checks, instrument qualification review, analyst proficiency — before the investigation moves to the supplier’s manufacturing process. Skipping that step doesn’t just weaken your scientific position; it can result in issuing a SCAR for a laboratory error, which damages your credibility with quality suppliers.

Writing a SCAR That Gets Results, Not Just Promises

A well-constructed SCAR has four functional sections. Each one does a specific job.

1. Non-conformance description. Be precise. Include the lot number, purchase order number, date received, the specific test parameter, your result with units, the specification limit with units, and the test method. “Failed potency test” is not a non-conformance description. “Lot XYZ-220415, withanolide content by HPLC-UV per Method QC-012 Rev. 3: result 2.1%, specification ≥5.0%” is.

2. Containment actions. Before issuing the SCAR, you should have already placed the non-conforming material on hold and physically segregated it. Document that in the SCAR. Note whether any downstream processing had already begun, and whether any product incorporating earlier lots from this supplier is currently in distribution. If it is, that’s a separate problem that needs to run concurrently.

3. Root cause analysis request. This is what separates a SCAR from a complaint. Ask specifically for a documented root cause analysis — not a narrative explanation, but a structured analysis (Fishbone diagram, 5-Why, or equivalent) that identifies the root cause, not a proximate one. Set a clear deadline: 30 calendar days for preliminary root cause findings is the industry standard, with 90 calendar days for full CAPA documentation and closure.

4. CAPA requirements. Define what an acceptable corrective action looks like. For a withanolide potency failure, that might include revised in-process extraction controls, updated finished goods QC testing at the supplier’s facility, and successful re-qualification testing on three consecutive production batches before you’ll accept routine shipments again. Vague CAPA language — “we will improve our process” — is unenforceable. Specific, measurable CAPA language gives you a basis for re-qualification and for escalation if the commitments aren’t met.

One formatting note that matters in practice: keep the SCAR document itself to 1–2 pages and attach test reports, raw data, and photographs as numbered annexes. A 15-page SCAR document tends to get diffused attention from supplier quality teams. A 2-page SCAR with 8 pages of clearly organized annexes demands a specific, organized response.

Escalation Criteria: When a SCAR Isn’t Enough

A single SCAR, resolved cleanly, can actually strengthen a supplier relationship — it demonstrates that your quality system is functional and that you hold quality to a defined standard. But there are scenarios where a SCAR is the beginning of a larger process, not an endpoint.

Escalate to a formal supplier audit when the SCAR root cause implicates systemic manufacturing or documentation practices; when the supplier’s CAPA response is late, incomplete, or not responsive to the specific question asked; or when this is the third SCAR from the same supplier within 24 months. At that point, you need qualified eyes on the facility — either your own quality team or a contracted third-party auditor who can evaluate the manufacturing environment, the quality management system, and the data integrity practices directly.

Escalate to a supplier disqualification review when a pattern of SCARs hasn’t produced measurable improvement, when a COA discrepancy investigation raises data integrity concerns, or when the supplier cannot produce evidence of a functioning quality management system. Disqualification isn’t purely a commercial decision — it’s a quality system action, and it should be documented as one.

Loop in regulatory affairs when non-conforming material has been released in error and incorporated into finished product already in distribution. At that point, you may be looking at a voluntary recall or a market withdrawal, and your quality and regulatory teams need to be aligned before any external communication goes out. The FDA has cited supplement manufacturers under 21 CFR Part 111.75 specifically for releasing components that failed to meet established specifications — and enforcement costs consistently exceed the cost of the incoming quality controls that would have prevented the failure.

The current regulatory environment reinforces why all of this matters. The FDA’s Office of Dietary Supplement Programs has maintained an active focus on supplier verification practices, and warning letters citing inadequate component testing and supplier qualification haven’t slowed. A reactive SCAR program — one that issues requests only after something dramatic fails — doesn’t satisfy the intent of 21 CFR Part 111. The intent is a systematic, documented approach to verifying that every component meets its specifications before it enters your product.

The Practical Starting Point

If your current SCAR process amounts to a strongly worded email, your quality system has a structural gap — and it’s one that shows up clearly during an FDA inspection or a third-party audit.

The mechanics matter: precise non-conformance language, complete analytical testing laboratory documentation, defined CAPA timelines, and clear escalation criteria are what transform a supplier complaint into an enforceable quality record. Start with the documentation layer. If you don’t have a contract analytical testing laboratory generating ISO 17025-aligned reports with full raw data retention, that’s the piece to fix first — because without it, your SCAR is an assertion, not evidence.

---

Written by Nour Abochama, VP Operations, Qalitex | Quality Consultant, Ayah Labs. Learn more about our team

Talk to our team about raw material testing. Contact us

Related from our network

• Raw material identity and purity testing services — Qalitex Laboratories offers ISO 17025-accredited analytical testing for supplement and cosmetic raw materials, with full data packages suitable for supplier qualification documentation.